Lilly Diabetes launches new Disney book for families affected by type 1 diabetes

Eli Lilly and CompanyLilly Diabetes has expanded its collection of resources for families of children with type 1 diabetes with the publication of Go, Team Coco! The story is the fourth Disney book in a series featuring Coco, a charismatic and fun-loving monkey who has type 1 diabetes. The book is available from most pediatric endocrinologists' offices in the U.S.

"Lilly Diabetes is proud to bring new resources featuring Disney content that has a positive impact on families living with type 1 diabetes," said Mike Mason, vice president U.S., Lilly Diabetes. "Since launching the first book four years ago, these stories have inspired and motivated children and families affected by the disease."

Go, Team Coco! is three stories in one book. Readers will learn about how Coco and her family cope with her diagnosis at the hospital, the new routines they establish at home, and her first follow-up visit to the doctor. Coco, along with other Disney characters, helps readers understand that with proper planning and management, children with diabetes and their families can still have fun and do things that children without the condition can do.

Each year, more than 18,000 children in the United States are diagnosed with type 1 diabetes.(1) For them and their families, the challenges of living with diabetes can be daunting. Through this collection of Disney stories, Lilly Diabetes sends empowering messages of inspiration, education, and practical advice to families with children who have type 1 diabetes-changing the focus from what they can't do to what they can do.

Go, Team Coco! is the latest in a series of books for young children in the Lilly Diabetes/Disney collection that also includes Coco and Goofy's Goofy Day, Coco Goes Back to School, and Coco's First Sleepover. A series of chapter books for older children is also available. All the books are available free of charge through pediatric endocrinologists' offices, and most are also accessible digitally at www.T1EverydayMagic.com, the Lilly Diabetes/Disney online destination dedicated to type 1 diabetes. Select titles have been translated into over 30 languages and are offered in more than 50 countries.

About Type 1 Diabetes
Type 1 diabetes occurs when the body does not produce insulin, a hormone that is needed to convert sugar into energy needed for daily life. As a result, a person requires daily administration of insulin to control their blood sugar.

While type 1 diabetes can affect people of any age, it usually occurs in children or young adults. By learning to manage their condition, people with type 1 diabetes can live long, healthy lives.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions-from medicines to support programs and more-we strive to make life better for all those affected by diabetes around the world.

About Eli Lilly and Company (NYSE: LLY)
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

1. "Fast Facts - Data and Statistics About Diabetes." Adapted from: American Diabetes Association, 2015. Available at: http://professional.diabetes.org/ResourcesForProfessionals.aspx?cid=91777&loc=dorg-statistics. Accessed May 15, 2015.

Most Popular Now

A step closer to cancer precision medicine

Researchers from the Faculty of Medicine and the Institute for Molecular Medicine (FIMM) at the University of Helsinki have developed a computational model, Combined Esse...

Artificial Intelligence algorithm can learn the la…

Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of resea...

Amgen completes acquisition of Otezla® (apremilast…

Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for mo...

Bristol-Myers Squibb completes acquisition of Celg…

Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all governmen...

Amgen and the Duke Clinical Research Institute ann…

Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Inves...

Statins not associated with memory or cognition de…

Given consumer concern that statins may be associated with memory or cognitive decline, a new study published today in the Journal of the American College of Cardiology m...

Novartis announces new strategy to provide innovat…

Novartis announced a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest unders...

Bayer and Dewpoint Therapeutics partner to researc…

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to ...

New advances in the treatment of advanced lung can…

The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic an...

Bristol-Myers Squibb and Pfizer announce randomize…

The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRi...

A protein tag to study the immune system

Researchers from VIB-UGent Center for Medical Biotechnology, University of Iowa (USA) and other collaborators, developed a novel approach to better understand a basic def...

FDA grants priority review to Roche’s risdiplam fo…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for ...